Cardiovascular Disorders Flashcards
(150 cards)
most common site of coronary artery occlusion
left anterior descending artery
heart region supplied by left anterior descending artery
anterior wall of left ventricle
heart region supplied by LAD septal branch
anterior 2/3 of interventricular septum
heart region supplied by left coronary circumflex branch
left atrium, posterolateral left ventricle
heart region supplied by right coronary posterior descending branch
inferior wall of left ventricle, posterior 1/3 of interventricular septum
heart region supplied by right coronary marginal branch
right atrium, right ventricle
heart region supplied by right coronary nodal branches
SA and AV nodes
gold standard for identifying coronary artery disease
coronary aniography
next step when exercise stress test is equivocal
nuclear exercise test with thallium-201 or technetium-99m-sestamibi during exercise testing
second line when comorbidities prevent exercise stress test
pharmacologic stress testing with dobutamine
age to begin screening for hyperlipidemia
men after age 35
women after age 45
goal LDL for patients at high risk for CAD
< 100 mg/dL
goal LDL for patients with 2+ risk factors for CAD
< 130 mg/dL
goal LDL for patients with 0-1 risk factors for CAD
< 160 mg/dL
HMG-CoA reductase inhibitors
acts on liver
decreases LDL and triglycerides
increases HDL
SE: myositis, increases LFTs
ezetimibe
cholesterol absorption inhibitor acts on intestines
decreases LDL
SE: myalgias, increases LFTs
gemfibrozil, fenofibrate
stimulates lipoprotein lipase in blood
decreases LDL and triglycerides
increases HDL
SE: myositis, increases LFTs
cholestyramine, colestipol, colesevelam
bile acid sequestrants in GI tract
decreases LDL
increases triglycerides
SE: bad taste, abdominal discomfort
niacin
acts on liver
decreases LDL, triglycerides
increases HDL
SE: flushing, nausea, pruritis, insulin resistance, gout, paresthesias, increases LFTs
vessels most commonly used for CABG
saphenous vein
internal mammary artery
pharmacotherapy for unstable angina
aspirin and clopidogrel (if no PTCA) GP IIb/IIIa (if PTCA) oxygen nitroglycerin heparin beta-blockers
time limit for thrombolysis in MI
12 hours
use t-Pa or urokinase
cardiac enzyme to evaluate immediate re-infarct
CPK-MB
decreases in 2-3 days
risk reduction medications after MI
low dose ASA clopidogrel beta-blockers ACE inhibitors K-sparing diuretics HMG-CoA reductase inhibitors exercise, smoking cessation, and dietary modifications